Evidence map›Paper›PMID 39590715›Full record

ArticleJournal of fungi (Basel, Switzerland)2024

The Rising Threat of Mucormycosis: Oman's Experience Before and During the COVID-19 Pandemic.

Amina Al-Jardani, Adil Al-Wahaibi, Azza Al Rashdi, Bram Spruijtenburg, Noora AlBulushi, R Sandhya Rani, Hanan AlKindi, Fatma Al-Yaquobi, Bader Al-Rawahi, Asma AlBalushi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Amina Al-JardaniCentral Public Health Laboratories, Center for Disease Control and Prevention, Ministry of Health, Muscat 100, Oman.
Adil Al-WahaibiSurveillance Department, Center for Disease Control and Prevention, Ministry of Health, Muscat 100, Oman.ORCID 0000-0002-5052-0800
Azza Al RashdiCentral Public Health Laboratories, Center for Disease Control and Prevention, Ministry of Health, Muscat 100, Oman.
Bram SpruijtenburgRadboudumc-CWZ Center of Expertise for Mycology, 6532 SZ Nijmegen, The Netherlands.
Noora AlBulushiCentral Public Health Laboratories, Center for Disease Control and Prevention, Ministry of Health, Muscat 100, Oman.
R Sandhya RaniCentral Public Health Laboratories, Center for Disease Control and Prevention, Ministry of Health, Muscat 100, Oman.
Hanan AlKindiCentral Public Health Laboratories, Center for Disease Control and Prevention, Ministry of Health, Muscat 100, Oman.
Fatma Al-YaquobiCommunicable Disease, Center for Disease Control and Prevention, Ministry of Health, Muscat 100, Oman.
Bader Al-RawahiCommunicable Disease, Center for Disease Control and Prevention, Ministry of Health, Muscat 100, Oman.
Asma AlBalushiInfectious Diseases Unit, Internal Medicine Department, Sultan Qaboos University Hospital, Muscat 123, Oman.ORCID 0000-0002-9836-4368
Saleh Al AzriCentral Public Health Laboratories, Center for Disease Control and Prevention, Ministry of Health, Muscat 100, Oman.
Jacques F MeisRadboudumc-CWZ Center of Expertise for Mycology, 6532 SZ Nijmegen, The Netherlands.ORCID 0000-0003-3253-6080
Iman AlBuloshiSurveillance Department, Disease Surveillance and Control, Directorate General of Health Services South Batinah Governorate, Ministry of Health, Muscat 100, Oman.
Seif Al-AbriInfectious Diseases Unit, Department of Medicine, Royal Hospital, Muscat 111, Oman.ORCID 0000-0002-2669-6814
Ahmed Al-HarrasiNatural and Medical Sciences Research Center, University of Nizwa, Nizwa 616, Oman.
Abdullah M S Al-HatmiRadboudumc-CWZ Center of Expertise for Mycology, 6532 SZ Nijmegen, The Netherlands.ORCID 0000-0002-5206-2647
Amal Al MaaniCenter for Disease Control and Prevention, Ministry of Health, Muscat 100, Oman.ORCID 0000-0001-8322-8331

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucormycosis is a rare, severe fungal infection mainly affecting immunocompromised individuals. Because of limited data on its epidemiology in Oman, we present this national, multicentric, retrospective review that includes all cases of proven mucormycosis between 2006 and 2022 in Oman. There were 51 cases of mucormycosis reported in Oman. The annual incidence of mucormycosis was 0.38-0.69 cases per million population before COVID-19. During the pandemic, the incidence rose significantly to 1.76 in 2020, 5.31 in 2021, then decreased to 0.87 per million population in 2022. Diabetes was observed in 82.4% (

Indexed as

COVID-19epidemiologymucormycosisOman

Identifiers

PMID39590715
PMCPMC11595873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.